Aspira Pathlab & Diagnostics Ltd

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd reached a fresh 52-week high of Rs 133 on 29 Jun 2026, marking a remarkable rally of over 156% in the past year. This milestone comes amid a sustained 13-day winning streak, underscoring the stock's robust price momentum despite a broader market that has struggled to maintain gains.

Extending a remarkable rally that has spanned several months, Aspira Pathlab & Diagnostics Ltd surged to a fresh all-time high of Rs 132.96 on 29 May 2026, marking a significant milestone for the healthcare services micro-cap. This price level caps a stunning 156.7% gain over the past year, vastly outpacing the Sensex, which has declined 7.1% over the same period.

Surging to an all-time high of Rs 130 on 27 May 2026, Aspira Pathlab & Diagnostics Ltd has demonstrated remarkable price momentum, doubling from its 52-week low of Rs 49 within the past year. This rally stands out amid a broadly subdued market backdrop, underscoring the stock’s technical resilience and sustained buying interest.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a fresh 52-week high of Rs 130 on 27 May 2026, marking a remarkable rally of over 135% from its low of Rs 49 in the past year. This milestone comes amid a sustained technical uptrend that has propelled the stock well above all key moving averages, signalling robust momentum in the healthcare services sector.

Extending a remarkable winning streak to 12 sessions, Aspira Pathlab & Diagnostics Ltd surged to a fresh all-time high of Rs 128.99 on 27 May 2026, marking a 102.21% gain over this period. This rally has significantly outpaced the Sensex, which declined 0.22% on the same day, underscoring the stock’s strong relative performance within the healthcare services sector.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a fresh 52-week high of Rs 124.5 on 26 Jun 2026, marking a remarkable rally of over 95% in just 11 consecutive trading sessions. This momentum has propelled the stock well above all key moving averages, signalling robust technical strength amid a broadly recovering market backdrop.

Aspira Pathlab & Diagnostics Ltd has reached a significant milestone by touching its all-time high price of Rs.122.95 on 26 May 2026, marking a remarkable phase in the company’s market journey within the healthcare services sector.

Aspira Pathlab & Diagnostics Ltd has witnessed a significant shift in its valuation parameters, moving from an expensive to a risky territory as per recent assessments. Despite a robust price rally, the company’s elevated price-to-earnings (P/E) and price-to-book value (P/BV) ratios, coupled with deteriorating profitability metrics, raise concerns about its price attractiveness relative to peers and historical benchmarks.

Surging past its previous peaks, Aspira Pathlab & Diagnostics Ltd touched a fresh 52-week high of Rs 118.9 on 25 Jun 2026, marking a remarkable rally of 113.10% over the past year. This milestone comes amid a sustained 10-day winning streak, underscoring the stock’s robust price momentum and technical alignment.

Surging to a fresh 52-week high of Rs 113 on 22 May 2026, Aspira Pathlab & Diagnostics Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market with a sustained rally that has spanned nine consecutive trading sessions.

The 50-day moving average for Aspira Pathlab & Diagnostics Ltd has crossed above the 200-day moving average, creating a golden cross on 21 May 2026. Yet, while this technical event often signals a shift towards bullish momentum, the broader technical and fundamental context presents a more nuanced picture.

Surging to an intraday peak of Rs 112.06 on 21 May 2026, Aspira Pathlab & Diagnostics Ltd has marked a significant milestone by reaching a fresh 52-week high. This achievement caps an impressive eight-day winning streak that has propelled the stock up by 72.74%, substantially outperforming its sector and the broader market.

With a remarkable 70.29% gain over the past seven days, Aspira Pathlab & Diagnostics Ltd surged to a fresh 52-week high of Rs 109 on 20 Jun 2026, defying the broader market's subdued tone and showcasing a powerful technical momentum that has captivated attention.

With a sustained six-day rally delivering a 63.85% gain, Aspira Pathlab & Diagnostics Ltd surged to a fresh 52-week high of Rs 104.52 on 19 Jun 2026, outpacing its healthcare services peers and the broader market.

Aspira Pathlab & Diagnostics Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 18 May 2026, driven primarily by a shift in technical indicators. However, valuation metrics and financial trends continue to weigh on the stock’s outlook, reflecting a complex investment case amid mixed signals from market data and company fundamentals.

Aspira Pathlab & Diagnostics Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating, prompting investors to reassess its price attractiveness amid strong recent returns and a micro-cap status within the healthcare services sector.